Novel extended release budesonide formulation for treatment of ulcerative colitis

Klaudia Farkas, T. Molnár

Research output: Contribution to journalArticle

Abstract

Introduction: Budesonide, a synthetic, non-halogenated corticosteroid, has been introduced in the topical treatment of ulcerative colitis (UC). Budesonide MMX, a novel, once-daily oral formulation of budesonide that uses a multi-matrix system (MMX) technology to extend the release of budesonide throughout the colon proved to be effective for the treatment of active UC. The focus of this review is the current status of budesonide MMX in extensive and left-sided UC. Areas covered: This paper covers the recent studies of budesonide MMX to describe its efficacy and safety in the treatment of mild-to-moderately active left-sided UC. A literature search and review of budesonide MMX were carried out using the PubMed database up to August 2013. Expert opinion: Clinical studies of budesonide MMX in adults with mild-to-moderately active UC demonstrated its efficacy and tolerability in achieving clinical and endoscopic remission. Although one trial is still ongoing, budesonide MMX 9 mg tablets represented the first orally administered topical corticosteroid formulation targeting the entire colon for the management of patients with active, mild-to-moderate UC.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Budesonide
Ulcerative Colitis
Therapeutics
Adrenal Cortex Hormones
Colon
Expert Testimony
PubMed
Tablets
Databases
Technology
Safety

Keywords

  • Budesonide
  • MMX formula
  • Topical activity
  • Ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Novel extended release budesonide formulation for treatment of ulcerative colitis. / Farkas, Klaudia; Molnár, T.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 1, 01.2014, p. 131-137.

Research output: Contribution to journalArticle

@article{3166522f301048268075be29bf16603b,
title = "Novel extended release budesonide formulation for treatment of ulcerative colitis",
abstract = "Introduction: Budesonide, a synthetic, non-halogenated corticosteroid, has been introduced in the topical treatment of ulcerative colitis (UC). Budesonide MMX, a novel, once-daily oral formulation of budesonide that uses a multi-matrix system (MMX) technology to extend the release of budesonide throughout the colon proved to be effective for the treatment of active UC. The focus of this review is the current status of budesonide MMX in extensive and left-sided UC. Areas covered: This paper covers the recent studies of budesonide MMX to describe its efficacy and safety in the treatment of mild-to-moderately active left-sided UC. A literature search and review of budesonide MMX were carried out using the PubMed database up to August 2013. Expert opinion: Clinical studies of budesonide MMX in adults with mild-to-moderately active UC demonstrated its efficacy and tolerability in achieving clinical and endoscopic remission. Although one trial is still ongoing, budesonide MMX 9 mg tablets represented the first orally administered topical corticosteroid formulation targeting the entire colon for the management of patients with active, mild-to-moderate UC.",
keywords = "Budesonide, MMX formula, Topical activity, Ulcerative colitis",
author = "Klaudia Farkas and T. Moln{\'a}r",
year = "2014",
month = "1",
doi = "10.1517/14656566.2014.860444",
language = "English",
volume = "15",
pages = "131--137",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Novel extended release budesonide formulation for treatment of ulcerative colitis

AU - Farkas, Klaudia

AU - Molnár, T.

PY - 2014/1

Y1 - 2014/1

N2 - Introduction: Budesonide, a synthetic, non-halogenated corticosteroid, has been introduced in the topical treatment of ulcerative colitis (UC). Budesonide MMX, a novel, once-daily oral formulation of budesonide that uses a multi-matrix system (MMX) technology to extend the release of budesonide throughout the colon proved to be effective for the treatment of active UC. The focus of this review is the current status of budesonide MMX in extensive and left-sided UC. Areas covered: This paper covers the recent studies of budesonide MMX to describe its efficacy and safety in the treatment of mild-to-moderately active left-sided UC. A literature search and review of budesonide MMX were carried out using the PubMed database up to August 2013. Expert opinion: Clinical studies of budesonide MMX in adults with mild-to-moderately active UC demonstrated its efficacy and tolerability in achieving clinical and endoscopic remission. Although one trial is still ongoing, budesonide MMX 9 mg tablets represented the first orally administered topical corticosteroid formulation targeting the entire colon for the management of patients with active, mild-to-moderate UC.

AB - Introduction: Budesonide, a synthetic, non-halogenated corticosteroid, has been introduced in the topical treatment of ulcerative colitis (UC). Budesonide MMX, a novel, once-daily oral formulation of budesonide that uses a multi-matrix system (MMX) technology to extend the release of budesonide throughout the colon proved to be effective for the treatment of active UC. The focus of this review is the current status of budesonide MMX in extensive and left-sided UC. Areas covered: This paper covers the recent studies of budesonide MMX to describe its efficacy and safety in the treatment of mild-to-moderately active left-sided UC. A literature search and review of budesonide MMX were carried out using the PubMed database up to August 2013. Expert opinion: Clinical studies of budesonide MMX in adults with mild-to-moderately active UC demonstrated its efficacy and tolerability in achieving clinical and endoscopic remission. Although one trial is still ongoing, budesonide MMX 9 mg tablets represented the first orally administered topical corticosteroid formulation targeting the entire colon for the management of patients with active, mild-to-moderate UC.

KW - Budesonide

KW - MMX formula

KW - Topical activity

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84890607645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890607645&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.860444

DO - 10.1517/14656566.2014.860444

M3 - Article

C2 - 24219763

AN - SCOPUS:84890607645

VL - 15

SP - 131

EP - 137

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -